Literature DB >> 11856782

The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.

Lutz T Weber1, Maria Shipkova1, Victor W Armstrong1, Natalie Wagner1, Ekkehard Schütz1, Otto Mehls1, Lothar B Zimmerhackl1, Michael Oellerich1, Burkhard Tönshoff1.   

Abstract

It is currently being debated whether pharmacokinetic monitoring of mycophenolic acid (MPA), the active constituent of mycophenolate mofetil (MMF), can optimize MMF therapy after organ transplantation. This open-label longitudinal study in pediatric renal transplant recipients was designed to investigate the pharmacokinetic (PK)/pharmacodynamic relationship of total and free MPA and to establish PK values for the assessment of an individual's MPA PK parameters. Fifty-four children, aged 2.2 to 17.8 yr, on an immunosuppressive triple regimen consisting of cyclosporin A, prednisone, and MMF (600 mg/m(2) body surface area twice daily) were investigated 1 wk and 3 wk (initial phase) and 3 mo and 6 mo (stable phase) after renal transplantation. MPA was measured by reverse phase HPLC, free MPA by HPLC after separation by ultrafiltration. There was an association between the risk of acute rejection episodes and MPA-AUC(0-12) values or MPA predose levels; by receiver operating characteristic analysis, an AUC(0-12) of 33.8 mg x h/L in the initial phase posttransplant had a diagnostic sensitivity of 75% and a diagnostic specificity of 64% for discrimination of patients with acute rejections. The respective discrimination threshold for the MPA predose concentration was 1.2 mg/L with a sensitivity of 83% and a specificity of 64%. In contrast, high free, but not total, MPA-AUC(0-12) values were associated with an increased risk of the MMF-related side effects leukopenia and/or infections. These data indicate that therapeutic drug monitoring of MPA has the potential for optimization of MMF efficacy in this patient population by steering patients away from the low values of MPA PK variables that are associated with an increased rejection risk. For the assessment of the toxic risk of MMF regarding leukopenia and/or infections, measurement of free MPA appears to be more appropriate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11856782     DOI: 10.1681/ASN.V133759

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  62 in total

1.  Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.

Authors:  Wai-Johnn Sam; Melanie S Joy
Journal:  Ther Drug Monit       Date:  2010-10       Impact factor: 3.681

2.  Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid.

Authors:  A Rother; P Glander; E Vitt; D Czock; N von Ahsen; V W Armstrong; M Oellerich; K Budde; R Feneberg; B Tönshoff; L T Weber
Journal:  Eur J Clin Pharmacol       Date:  2012-01-25       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Melanie S Joy; Tandrea Hilliard; Yichun Hu; Susan L Hogan; Jinzhao Wang; Ronald J Falk; Philip C Smith
Journal:  Ann Pharmacother       Date:  2009-06-02       Impact factor: 3.154

5.  Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation.

Authors:  Elias David-Neto; Lilian Monteiro Pereira Araujo; Nairo Massakazu Sumita; Maria Elizabeth Mendes; Maria Cristina Ribeiro Castro; Cristiane Feres Alves; Erica Kakehashi; Paschoalina Romano; Elisa Midori Yagyu; Margaret Queiroga; William Carlos Nahas; Luiz Estevam Ianhez
Journal:  Pediatr Nephrol       Date:  2003-02-22       Impact factor: 3.714

6.  Mycophenolate mofetil for sustained remission in nephrotic syndrome.

Authors:  Uwe Querfeld; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2018-05-11       Impact factor: 3.714

7.  The utility of trough mycophenolic acid levels for the management of lupus nephritis.

Authors:  Negiin Pourafshar; Ashkan Karimi; Xuerong Wen; Eric Sobel; Shirin Pourafshar; Nikhil Agrawal; Emma Segal; Rajesh Mohandas; Mark S Segal
Journal:  Nephrol Dial Transplant       Date:  2019-01-01       Impact factor: 5.992

8.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

Authors:  Bronwyn A Atcheson; Paul J Taylor; David W Mudge; David W Johnson; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; Peter I Pillans; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

9.  Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

Authors:  Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

Review 10.  To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.

Authors:  Guido Filler; Nathalie Lepage
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.